GH Research (GHRS) Stock Price, News & Analysis

Company Overview

GH Research plc is a clinical-stage biopharmaceutical company focused on developing novel therapies for psychiatric and neurological disorders. The company is headquartered in Dublin, Ireland, and conducts research and clinical development activities through its proprietary pipeline of psychedelic-based medicines.

Its lead program, GH001, is an investigational inhaled formulation of mebufotenin, also known as 5-MeO-DMT. GH Research has studied GH001 in patients with treatment-resistant depression, with the aim of developing a rapidly acting treatment that may provide meaningful improvements following a short course of administration. The company is also advancing additional product candidates, including GH002, which is designed to provide an alternative formulation and delivery approach for mebufotenin.

GH Research's programs remain investigational and are subject to clinical testing and regulatory review. The company was founded in 2018 and has focused its development efforts on potential treatments for serious psychiatric conditions with substantial unmet medical needs.

Key Stats

• Today's Range: $18.75 to $20.22
• 50-Day Range: $18.07 to $29.80
• 52-Week Range: $12.04 to $31.44
• Volume: 299,971 shs
• Average Volume: N/A
• Market Capitalization: $1.37 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.00
• Consensus Rating: Moderate Buy

GH Research Stock Analysis - MarketRank™

GH Research scored higher than 62% of companies evaluated by MarketBeat, and ranked 429th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

GH Research has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

GH Research has a consensus price target of $45.00, representing about 124.8% upside from its current price of $20.02.

Amount of Analyst Coverage

GH Research has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for GH Research are expected to decrease in the coming year, from ($1.20) to ($2.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GH Research is -20.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GH Research is -20.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.93% of the float of GH Research has been sold short.

Short Interest Ratio / Days to Cover

GH Research has a short interest ratio ("days to cover") of 7.03.

Change versus previous month

Short interest in GH Research has recently increased by 14.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GH Research does not currently pay a dividend.

Dividend Growth

GH Research does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.99

News Sentiment

GH Research has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for GH Research this week, compared to 2 articles on an average week.

Search Interest

Only 7 people have searched for GHRS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GH Research insiders have not sold or bought any company stock.

Percentage Held by Institutions

56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:GHRS
• CIK: 1855129
• Web: www.ghres.com
• Phone: 212-450-4000
• Fax: N/A
• Employees: 73
• Year Founded: 2018

Price Target and Rating

• Average Price Target for GH Research: $45.00
• High Price Target: $65.00
• Low Price Target: $39.00
• Potential Upside/Downside: +124.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 68,609,000
• Free Float: N/A
• Market Cap: $1.37 billion
• Optionable: Optionable
• Beta: 1.32